Atomo Diagnostics Ltd. (AU:AT1) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Atomo Diagnostics Ltd. is set to increase its revenue through government-funded expansion of its HIV self-testing programs in Australia, with an anticipated $1.3 million from the national mail-out program and broader deployment of vending machines offering free HIV self-tests. The company, which provides the only HIV Self-Test on the Australian Register of Therapeutic Goods, sees this as a continuation of the shift towards decentralized public health services post-COVID-19, and expects a wider adoption of at-home testing for various infectious diseases.
For further insights into AU:AT1 stock, check out TipRanks’ Stock Analysis page.